These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18946746)

  • 41. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
    Zgliczyński S; Borówka A
    Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713
    [No Abstract]   [Full Text] [Related]  

  • 42. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Brown RJ; Davidson NE
    Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer.
    Higgins GS; Stewart GD; McNeill SA; McLaren DB
    Int J Clin Pract; 2007 Dec; 61(12):1964-5. PubMed ID: 17997800
    [No Abstract]   [Full Text] [Related]  

  • 45. Hormonal treatment of endometrial cancer: past, present and future.
    Podczaski E; Mortel R
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):469-89. PubMed ID: 11476566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Revaluation of estrogen therapy on prostate cancer].
    Takezawa Y; Kobayashi M; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():223-7. PubMed ID: 11022718
    [No Abstract]   [Full Text] [Related]  

  • 47. Editorial: hormone therapies for prostate cancer--acute disease control, chronic disease progression.
    Lamb DJ; Buttyan R
    J Urol; 2003 Apr; 169(4):1558. PubMed ID: 12629414
    [No Abstract]   [Full Text] [Related]  

  • 48. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 51. [Primary multiple neoplasm of the endometrium and adjuvant hormone therapy in patients with breast cancer].
    Bakhidze EV; Maksimov SIa; Barash NIu; Berstein LM; Semiglazov VF; Sheĭko EV; Novik VI
    Vopr Onkol; 1998; 44(2):170-4. PubMed ID: 9615821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Kahán Z
    Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
    [No Abstract]   [Full Text] [Related]  

  • 53. [Biomarkers of endocrine therapy-resistance in breast cancers].
    de Cremoux P; Debled M; Bonnefoi H; Cottu P
    Bull Cancer; 2010 Aug; 97(8):951-63. PubMed ID: 20605764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of mifepristone approval on research remains to be seen.
    Vastag B
    J Natl Cancer Inst; 2000 Dec; 92(24):1970-1. PubMed ID: 11121453
    [No Abstract]   [Full Text] [Related]  

  • 55. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
    Nicholson RI; Hutcheson IR; Britton D; Knowlden JM; Jones HE; Harper ME; Hiscox SE; Barrow D; Gee JM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):257-62. PubMed ID: 15860268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy.
    Lebret T; Coloby P; Descotes JL; Droupy S; Geraud M; Tombal B
    Urology; 2010 Dec; 76(6):1434-9. PubMed ID: 21130255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer. Proceedings of the 5th International Conference, Cambridge, Massachusetts, USA, June 13-14, 2005.
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):997s-1068s. PubMed ID: 16541524
    [No Abstract]   [Full Text] [Related]  

  • 58. Proceedings of the 2nd International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer. Cambridge, Massachusetts, USA, June 28-29, 2002.
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):443S-532S; quiz i-vi. PubMed ID: 12838958
    [No Abstract]   [Full Text] [Related]  

  • 59. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis.
    Ethier JL; Desautels DN; Amir E; MacKay H
    Gynecol Oncol; 2017 Oct; 147(1):158-166. PubMed ID: 28689667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormonal treatment of endometrial cancer.
    Emons G; Heyl W
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):619-23. PubMed ID: 11079725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.